Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531–2544. https://doi.org/10.1056/NEJMoa1707447

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evans AG, Rothberg PG, Burack WR, Huntington SF, Porter DL, Friedberg JW, Liesveld JL (2015) Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells. Br J Haematol 171(2):205–209. https://doi.org/10.1111/bjh.13562

Article  CAS  PubMed  Google Scholar 

Zhang Q, Orlando EJ, Wang HY, Bogusz AM, Liu X, Lacey SF, Strauser HT, Nunez-Cruz S, Nejati R, Zhang P, Brooks S, Watt C, Melenhorst JJ, June CH, Schuster SJ, Wasik MA (2020) Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome. Blood 136(17):1980–1983. https://doi.org/10.1182/blood.2020005123

Article  PubMed  PubMed Central  Google Scholar 

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282. https://doi.org/10.1182/blood-2003-05-1545

Article  CAS  PubMed  Google Scholar 

Garcia EP, Minkovsky A, Jia Y, Ducar MD, Shivdasani P, Gong X, Ligon AH, Sholl LM, Kuo FC, MacConaill LE, Lindeman NI, Dong F (2017) Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch Pathol Lab Med 141(6):751–758. https://doi.org/10.5858/arpa.2016-0527-OA

Article  CAS  PubMed  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, Mehta A, Purev E, Maloney DG, Andreadis C, Sehgal A, Solomon SR, Ghosh N, Albertson TM, Garcia J, Kostic A, Mallaney M, Ogasawara K, Newhall K, Kim Y, Li D, Siddiqi T (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839–852. https://doi.org/10.1016/S0140-6736(20)31366-0

Article  PubMed  Google Scholar 

Feldman AL, Arber DA, Pittaluga S, Martinez A, Burke JS, Raffeld M, Camos M, Warnke R, Jaffe ES (2008) Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood 111(12):5433–5439. https://doi.org/10.1182/blood-2007-11-124792

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hure MC, Elco CP, Ward D, Hutchinson L, Meng X, Dorfman DM, Yu H (2012) Histiocytic sarcoma arising from clonally related mantle cell lymphoma. J Clin Oncol 30(5):e49-53. https://doi.org/10.1200/JCO.2011.38.8553

Article  PubMed  Google Scholar 

Ambrosio MR, De Falco G, Rocca BJ, Barone A, Amato T, Bellan C, Lazzi S, Leoncini L (2015) Langerhans cell sarcoma following marginal zone lymphoma: expanding the knowledge on mature B cell plasticity. Virchows Arch 467(4):471–480. https://doi.org/10.1007/s00428-015-1814-8

Article  CAS  PubMed  Google Scholar 

Laurent C, Syrykh C, Hamon M, Adélaïde J, Guille A, Escudié F, Jalowicki G, Fina F, Bardet A, Mescam L, Molina TJ, Dartigues P, Parrens M, Sujobert P, Besson C, Birnbaum D, Xerri L (2022) Resistance of B-cell lymphomas to CAR T-cell therapy is associated with genomic tumor changes which can result in transdifferentiation. Am J Surg Pathol 46(6):742–753. https://doi.org/10.1097/PAS.0000000000001834

Article  PubMed  Google Scholar 

Sworder BJ, Kurtz DM, Alig SK, Frank MJ, Shukla N, Garofalo A, Macaulay CW, Shahrokh Esfahani M, Olsen MN, Hamilton J, Hosoya H, Hamilton M, Spiegel JY, Baird JH, Sugio T, Carleton M, Craig AFM, Younes SF, Sahaf B, Sheybani ND, Schroers-Martin JG, Liu CL, Oak JS, Jin MC, Beygi S, Hüttmann A, Hanoun C, Dührsen U, Westin JR, Khodadoust MS, Natkunam Y, Majzner RG, Mackall CL, Diehn M, Miklos DB, Alizadeh AA (2023) Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell 41(1):210-225.e5. https://doi.org/10.1016/j.ccell.2022.12.005

Article  CAS  PubMed  Google Scholar 

Zhou J, Zhang W, Zhang Y, Zheng S, Zhou L, Yang X, Wang C (2020) Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls. Am J Transl Res. 12(10):6751–6762 Erratum in: Am J Transl Res. 2022;14(1):693-694

CAS  PubMed  PubMed Central  Google Scholar